http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 01 Jun 2026 16:16:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++144++++++++EXELIXIS%2C+INC.+++++++++++++++++++++++++Filed+by%3A+Eckhardt+Sue+Gail/26583873.html si-local-file:///var/storage/secattach/20260601/26583873.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++EXELIXIS%2C+INC.+++++++++++++++++++++++++Filed+by%3A+Eckhardt+Sue+Gail/26583873.html Mon, 01 Jun 2026 16:16:00 -0400 EXEL O.00180634 http://www.streetinsider.com/SEC+Filings/Form++144++++++++EXELIXIS%2C+INC.+++++++++++++++++++++++++Filed+by%3A+Eckhardt+Sue+Gail/26583873.html si-local-file:///var/storage/secattach/20260601/26583873.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++EXELIXIS%2C+INC.+++++++++++++++++++++++++Filed+by%3A+Eckhardt+Sue+Gail/26583873.html Mon, 01 Jun 2026 16:16:00 -0400 EXEL O.00180634 http://www.streetinsider.com/SEC+Filings/Form++144++++++++EXELIXIS%2C+INC.+++++++++++++++++++++++++Filed+by%3A+WYSZOMIERSKI+JACK+L/26583466.html si-local-file:///var/storage/secattach/20260601/26583466.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++EXELIXIS%2C+INC.+++++++++++++++++++++++++Filed+by%3A+WYSZOMIERSKI+JACK+L/26583466.html Mon, 01 Jun 2026 16:05:00 -0400 EXEL O.00180634 http://www.streetinsider.com/SEC+Filings/Form++144++++++++EXELIXIS%2C+INC.+++++++++++++++++++++++++Filed+by%3A+WYSZOMIERSKI+JACK+L/26583466.html si-local-file:///var/storage/secattach/20260601/26583466.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++EXELIXIS%2C+INC.+++++++++++++++++++++++++Filed+by%3A+WYSZOMIERSKI+JACK+L/26583466.html Mon, 01 Jun 2026 16:05:00 -0400 EXEL O.00180634 http://www.streetinsider.com/FDA/Exelixis+reports+Cabometyx+trial+results+for+neuroendocrine+tumors/26577215.html <p>Exelixis Inc. (NASDAQ: EXEL) reported subgroup analysis results from its phase 3 CABINET trial showing that Cabometyx reduced the risk of disease progression or death by 74% in patients with non-functional neuroendocrine tumors and by 60% in patients with functional neuroendocrine tumors compared to placebo.</p> <p>The data was presented at the American Society of Clinical Oncology Annual Meeting. In the trial, 298 patients with locally advanced or metastatic pancreatic or extra-pancreatic neuroendocrine tumors were randomized to receive Cabometyx 60 mg daily or placebo in a 2:1 ratio.</p> <p>For patients with non-functional tumors, median progression-free survival was 9.4 months with Cabometyx versus 3.1 http://www.streetinsider.com/FDA/Exelixis+reports+Cabometyx+trial+results+for+neuroendocrine+tumors/26577215.html Sat, 30 May 2026 10:00:17 -0400 A.19655944 A.50216726 A.60001765 EXEL O.00180634 O.03307993 O.20738543 O.21612337 http://www.streetinsider.com/FDA/Exelixis+reports+Cabometyx+trial+results+for+neuroendocrine+tumors/26577215.html <p>Exelixis Inc. (NASDAQ: EXEL) reported subgroup analysis results from its phase 3 CABINET trial showing that Cabometyx reduced the risk of disease progression or death by 74% in patients with non-functional neuroendocrine tumors and by 60% in patients with functional neuroendocrine tumors compared to placebo.</p> <p>The data was presented at the American Society of Clinical Oncology Annual Meeting. In the trial, 298 patients with locally advanced or metastatic pancreatic or extra-pancreatic neuroendocrine tumors were randomized to receive Cabometyx 60 mg daily or placebo in a 2:1 ratio.</p> <p>For patients with non-functional tumors, median progression-free survival was 9.4 months with Cabometyx versus 3.1 http://www.streetinsider.com/FDA/Exelixis+reports+Cabometyx+trial+results+for+neuroendocrine+tumors/26577215.html Sat, 30 May 2026 10:00:17 -0400 A.19655944 A.50216726 A.60001765 EXEL O.00180634 O.03307993 O.20738543 O.21612337 http://www.streetinsider.com/FDA/Exelixis+reports+Cabometyx+trial+results+for+neuroendocrine+tumors/26577215.html <p>Exelixis Inc. (NASDAQ: EXEL) reported subgroup analysis results from its phase 3 CABINET trial showing that Cabometyx reduced the risk of disease progression or death by 74% in patients with non-functional neuroendocrine tumors and by 60% in patients with functional neuroendocrine tumors compared to placebo.</p> <p>The data was presented at the American Society of Clinical Oncology Annual Meeting. In the trial, 298 patients with locally advanced or metastatic pancreatic or extra-pancreatic neuroendocrine tumors were randomized to receive Cabometyx 60 mg daily or placebo in a 2:1 ratio.</p> <p>For patients with non-functional tumors, median progression-free survival was 9.4 months with Cabometyx versus 3.1 http://www.streetinsider.com/FDA/Exelixis+reports+Cabometyx+trial+results+for+neuroendocrine+tumors/26577215.html Sat, 30 May 2026 10:00:17 -0400 A.19655944 A.50216726 A.60001765 EXEL O.00180634 O.03307993 O.20738543 O.21612337 http://www.streetinsider.com/FDA/Exelixis+reports+Cabometyx+trial+results+for+neuroendocrine+tumors/26577215.html <p>Exelixis Inc. (NASDAQ: EXEL) reported subgroup analysis results from its phase 3 CABINET trial showing that Cabometyx reduced the risk of disease progression or death by 74% in patients with non-functional neuroendocrine tumors and by 60% in patients with functional neuroendocrine tumors compared to placebo.</p> <p>The data was presented at the American Society of Clinical Oncology Annual Meeting. In the trial, 298 patients with locally advanced or metastatic pancreatic or extra-pancreatic neuroendocrine tumors were randomized to receive Cabometyx 60 mg daily or placebo in a 2:1 ratio.</p> <p>For patients with non-functional tumors, median progression-free survival was 9.4 months with Cabometyx versus 3.1 http://www.streetinsider.com/FDA/Exelixis+reports+Cabometyx+trial+results+for+neuroendocrine+tumors/26577215.html Sat, 30 May 2026 10:00:17 -0400 A.19655944 A.50216726 A.60001765 EXEL O.00180634 O.03307993 O.20738543 O.21612337 http://www.streetinsider.com/FDA/Exelixis+reports+Cabometyx+trial+results+for+neuroendocrine+tumors/26577215.html <p>Exelixis Inc. (NASDAQ: EXEL) reported subgroup analysis results from its phase 3 CABINET trial showing that Cabometyx reduced the risk of disease progression or death by 74% in patients with non-functional neuroendocrine tumors and by 60% in patients with functional neuroendocrine tumors compared to placebo.</p> <p>The data was presented at the American Society of Clinical Oncology Annual Meeting. In the trial, 298 patients with locally advanced or metastatic pancreatic or extra-pancreatic neuroendocrine tumors were randomized to receive Cabometyx 60 mg daily or placebo in a 2:1 ratio.</p> <p>For patients with non-functional tumors, median progression-free survival was 9.4 months with Cabometyx versus 3.1 http://www.streetinsider.com/FDA/Exelixis+reports+Cabometyx+trial+results+for+neuroendocrine+tumors/26577215.html Sat, 30 May 2026 10:00:17 -0400 A.19655944 A.50216726 A.60001765 EXEL O.00180634 O.03307993 O.20738543 O.21612337 http://www.streetinsider.com/FDA/Exelixis+reports+Cabometyx+trial+results+for+neuroendocrine+tumors/26577215.html <p>Exelixis Inc. (NASDAQ: EXEL) reported subgroup analysis results from its phase 3 CABINET trial showing that Cabometyx reduced the risk of disease progression or death by 74% in patients with non-functional neuroendocrine tumors and by 60% in patients with functional neuroendocrine tumors compared to placebo.</p> <p>The data was presented at the American Society of Clinical Oncology Annual Meeting. In the trial, 298 patients with locally advanced or metastatic pancreatic or extra-pancreatic neuroendocrine tumors were randomized to receive Cabometyx 60 mg daily or placebo in a 2:1 ratio.</p> <p>For patients with non-functional tumors, median progression-free survival was 9.4 months with Cabometyx versus 3.1 http://www.streetinsider.com/FDA/Exelixis+reports+Cabometyx+trial+results+for+neuroendocrine+tumors/26577215.html Sat, 30 May 2026 10:00:17 -0400 A.19655944 A.50216726 A.60001765 EXEL O.00180634 O.03307993 O.20738543 O.21612337 http://www.streetinsider.com/FDA/Exelixis+reports+Cabometyx+trial+results+for+neuroendocrine+tumors/26577215.html <p>Exelixis Inc. (NASDAQ: EXEL) reported subgroup analysis results from its phase 3 CABINET trial showing that Cabometyx reduced the risk of disease progression or death by 74% in patients with non-functional neuroendocrine tumors and by 60% in patients with functional neuroendocrine tumors compared to placebo.</p> <p>The data was presented at the American Society of Clinical Oncology Annual Meeting. In the trial, 298 patients with locally advanced or metastatic pancreatic or extra-pancreatic neuroendocrine tumors were randomized to receive Cabometyx 60 mg daily or placebo in a 2:1 ratio.</p> <p>For patients with non-functional tumors, median progression-free survival was 9.4 months with Cabometyx versus 3.1 http://www.streetinsider.com/FDA/Exelixis+reports+Cabometyx+trial+results+for+neuroendocrine+tumors/26577215.html Sat, 30 May 2026 10:00:17 -0400 A.19655944 A.50216726 A.60001765 EXEL O.00180634 O.03307993 O.20738543 O.21612337 http://www.streetinsider.com/FDA/Exelixis+reports+Cabometyx+trial+results+for+neuroendocrine+tumors/26577215.html <p>Exelixis Inc. (NASDAQ: EXEL) reported subgroup analysis results from its phase 3 CABINET trial showing that Cabometyx reduced the risk of disease progression or death by 74% in patients with non-functional neuroendocrine tumors and by 60% in patients with functional neuroendocrine tumors compared to placebo.</p> <p>The data was presented at the American Society of Clinical Oncology Annual Meeting. In the trial, 298 patients with locally advanced or metastatic pancreatic or extra-pancreatic neuroendocrine tumors were randomized to receive Cabometyx 60 mg daily or placebo in a 2:1 ratio.</p> <p>For patients with non-functional tumors, median progression-free survival was 9.4 months with Cabometyx versus 3.1 http://www.streetinsider.com/FDA/Exelixis+reports+Cabometyx+trial+results+for+neuroendocrine+tumors/26577215.html Sat, 30 May 2026 10:00:17 -0400 A.19655944 A.50216726 A.60001765 EXEL O.00180634 O.03307993 O.20738543 O.21612337 http://www.streetinsider.com/Press+Releases/Exelixis+Announces+Results+from+Subgroup+Analysis+of+Phase+3+CABINET+Pivotal+Trial+Evaluating+CABOMETYX%C2%AE+%28cabozantinib%29+in+Non-Functional+and+Functional+Neuroendocrine+Tumors+at+ASCO+2026/26577214.html <p class="bwalignc"> <i>– CABOMETYX significantly reduced the risk of disease progression or death by 74% and 60% in patients with non-functional and functional advanced NET, respectively, versus placebo –</i> </p> <p> ALAMEDA, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.exelixis.com%2F&amp;esheet=54544202&amp;newsitemid=20260529816966&amp;lan=en-US&amp;anchor=Exelixis%2C+Inc.&amp;index=1&amp;md5=f477e6e10704015cd700297fbc4c73ce" shape="rect">Exelixis, Inc.</a> (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal trial, which showed that CABOMETYX® (cabozantinib) provided significant improvements in progression-free survival (PFS) versus placebo in patients with previously treated advanced neuroendocrine tumors (NET) regardless of functional status. These data will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting to be http://www.streetinsider.com/Press+Releases/Exelixis+Announces+Results+from+Subgroup+Analysis+of+Phase+3+CABINET+Pivotal+Trial+Evaluating+CABOMETYX%C2%AE+%28cabozantinib%29+in+Non-Functional+and+Functional+Neuroendocrine+Tumors+at+ASCO+2026/26577214.html Sat, 30 May 2026 10:00:00 -0400 A.19655944 A.50216726 A.60001765 EXEL O.00180634 O.03307993 O.20738543 O.21612337 http://www.streetinsider.com/Press+Releases/Exelixis+Announces+Results+from+Subgroup+Analysis+of+Phase+3+CABINET+Pivotal+Trial+Evaluating+CABOMETYX%C2%AE+%28cabozantinib%29+in+Non-Functional+and+Functional+Neuroendocrine+Tumors+at+ASCO+2026/26577214.html <p class="bwalignc"> <i>– CABOMETYX significantly reduced the risk of disease progression or death by 74% and 60% in patients with non-functional and functional advanced NET, respectively, versus placebo –</i> </p> <p> ALAMEDA, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.exelixis.com%2F&amp;esheet=54544202&amp;newsitemid=20260529816966&amp;lan=en-US&amp;anchor=Exelixis%2C+Inc.&amp;index=1&amp;md5=f477e6e10704015cd700297fbc4c73ce" shape="rect">Exelixis, Inc.</a> (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal trial, which showed that CABOMETYX® (cabozantinib) provided significant improvements in progression-free survival (PFS) versus placebo in patients with previously treated advanced neuroendocrine tumors (NET) regardless of functional status. These data will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting to be http://www.streetinsider.com/Press+Releases/Exelixis+Announces+Results+from+Subgroup+Analysis+of+Phase+3+CABINET+Pivotal+Trial+Evaluating+CABOMETYX%C2%AE+%28cabozantinib%29+in+Non-Functional+and+Functional+Neuroendocrine+Tumors+at+ASCO+2026/26577214.html Sat, 30 May 2026 10:00:00 -0400 A.19655944 A.50216726 A.60001765 EXEL O.00180634 O.03307993 O.20738543 O.21612337 http://www.streetinsider.com/Press+Releases/Exelixis+Announces+Results+from+Subgroup+Analysis+of+Phase+3+CABINET+Pivotal+Trial+Evaluating+CABOMETYX%C2%AE+%28cabozantinib%29+in+Non-Functional+and+Functional+Neuroendocrine+Tumors+at+ASCO+2026/26577214.html <p class="bwalignc"> <i>– CABOMETYX significantly reduced the risk of disease progression or death by 74% and 60% in patients with non-functional and functional advanced NET, respectively, versus placebo –</i> </p> <p> ALAMEDA, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.exelixis.com%2F&amp;esheet=54544202&amp;newsitemid=20260529816966&amp;lan=en-US&amp;anchor=Exelixis%2C+Inc.&amp;index=1&amp;md5=f477e6e10704015cd700297fbc4c73ce" shape="rect">Exelixis, Inc.</a> (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal trial, which showed that CABOMETYX® (cabozantinib) provided significant improvements in progression-free survival (PFS) versus placebo in patients with previously treated advanced neuroendocrine tumors (NET) regardless of functional status. These data will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting to be http://www.streetinsider.com/Press+Releases/Exelixis+Announces+Results+from+Subgroup+Analysis+of+Phase+3+CABINET+Pivotal+Trial+Evaluating+CABOMETYX%C2%AE+%28cabozantinib%29+in+Non-Functional+and+Functional+Neuroendocrine+Tumors+at+ASCO+2026/26577214.html Sat, 30 May 2026 10:00:00 -0400 A.19655944 A.50216726 A.60001765 EXEL O.00180634 O.03307993 O.20738543 O.21612337 http://www.streetinsider.com/Press+Releases/Exelixis+Announces+Results+from+Subgroup+Analysis+of+Phase+3+CABINET+Pivotal+Trial+Evaluating+CABOMETYX%C2%AE+%28cabozantinib%29+in+Non-Functional+and+Functional+Neuroendocrine+Tumors+at+ASCO+2026/26577214.html <p class="bwalignc"> <i>– CABOMETYX significantly reduced the risk of disease progression or death by 74% and 60% in patients with non-functional and functional advanced NET, respectively, versus placebo –</i> </p> <p> ALAMEDA, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.exelixis.com%2F&amp;esheet=54544202&amp;newsitemid=20260529816966&amp;lan=en-US&amp;anchor=Exelixis%2C+Inc.&amp;index=1&amp;md5=f477e6e10704015cd700297fbc4c73ce" shape="rect">Exelixis, Inc.</a> (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal trial, which showed that CABOMETYX® (cabozantinib) provided significant improvements in progression-free survival (PFS) versus placebo in patients with previously treated advanced neuroendocrine tumors (NET) regardless of functional status. These data will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting to be http://www.streetinsider.com/Press+Releases/Exelixis+Announces+Results+from+Subgroup+Analysis+of+Phase+3+CABINET+Pivotal+Trial+Evaluating+CABOMETYX%C2%AE+%28cabozantinib%29+in+Non-Functional+and+Functional+Neuroendocrine+Tumors+at+ASCO+2026/26577214.html Sat, 30 May 2026 10:00:00 -0400 A.19655944 A.50216726 A.60001765 EXEL O.00180634 O.03307993 O.20738543 O.21612337 http://www.streetinsider.com/Press+Releases/Exelixis+Announces+Results+from+Subgroup+Analysis+of+Phase+3+CABINET+Pivotal+Trial+Evaluating+CABOMETYX%C2%AE+%28cabozantinib%29+in+Non-Functional+and+Functional+Neuroendocrine+Tumors+at+ASCO+2026/26577214.html <p class="bwalignc"> <i>– CABOMETYX significantly reduced the risk of disease progression or death by 74% and 60% in patients with non-functional and functional advanced NET, respectively, versus placebo –</i> </p> <p> ALAMEDA, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.exelixis.com%2F&amp;esheet=54544202&amp;newsitemid=20260529816966&amp;lan=en-US&amp;anchor=Exelixis%2C+Inc.&amp;index=1&amp;md5=f477e6e10704015cd700297fbc4c73ce" shape="rect">Exelixis, Inc.</a> (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal trial, which showed that CABOMETYX® (cabozantinib) provided significant improvements in progression-free survival (PFS) versus placebo in patients with previously treated advanced neuroendocrine tumors (NET) regardless of functional status. These data will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting to be http://www.streetinsider.com/Press+Releases/Exelixis+Announces+Results+from+Subgroup+Analysis+of+Phase+3+CABINET+Pivotal+Trial+Evaluating+CABOMETYX%C2%AE+%28cabozantinib%29+in+Non-Functional+and+Functional+Neuroendocrine+Tumors+at+ASCO+2026/26577214.html Sat, 30 May 2026 10:00:00 -0400 A.19655944 A.50216726 A.60001765 EXEL O.00180634 O.03307993 O.20738543 O.21612337 http://www.streetinsider.com/Press+Releases/Exelixis+Announces+Results+from+Subgroup+Analysis+of+Phase+3+CABINET+Pivotal+Trial+Evaluating+CABOMETYX%C2%AE+%28cabozantinib%29+in+Non-Functional+and+Functional+Neuroendocrine+Tumors+at+ASCO+2026/26577214.html <p class="bwalignc"> <i>– CABOMETYX significantly reduced the risk of disease progression or death by 74% and 60% in patients with non-functional and functional advanced NET, respectively, versus placebo –</i> </p> <p> ALAMEDA, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.exelixis.com%2F&amp;esheet=54544202&amp;newsitemid=20260529816966&amp;lan=en-US&amp;anchor=Exelixis%2C+Inc.&amp;index=1&amp;md5=f477e6e10704015cd700297fbc4c73ce" shape="rect">Exelixis, Inc.</a> (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal trial, which showed that CABOMETYX® (cabozantinib) provided significant improvements in progression-free survival (PFS) versus placebo in patients with previously treated advanced neuroendocrine tumors (NET) regardless of functional status. These data will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting to be http://www.streetinsider.com/Press+Releases/Exelixis+Announces+Results+from+Subgroup+Analysis+of+Phase+3+CABINET+Pivotal+Trial+Evaluating+CABOMETYX%C2%AE+%28cabozantinib%29+in+Non-Functional+and+Functional+Neuroendocrine+Tumors+at+ASCO+2026/26577214.html Sat, 30 May 2026 10:00:00 -0400 A.19655944 A.50216726 A.60001765 EXEL O.00180634 O.03307993 O.20738543 O.21612337 http://www.streetinsider.com/Press+Releases/Exelixis+Announces+Results+from+Subgroup+Analysis+of+Phase+3+CABINET+Pivotal+Trial+Evaluating+CABOMETYX%C2%AE+%28cabozantinib%29+in+Non-Functional+and+Functional+Neuroendocrine+Tumors+at+ASCO+2026/26577214.html <p class="bwalignc"> <i>– CABOMETYX significantly reduced the risk of disease progression or death by 74% and 60% in patients with non-functional and functional advanced NET, respectively, versus placebo –</i> </p> <p> ALAMEDA, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.exelixis.com%2F&amp;esheet=54544202&amp;newsitemid=20260529816966&amp;lan=en-US&amp;anchor=Exelixis%2C+Inc.&amp;index=1&amp;md5=f477e6e10704015cd700297fbc4c73ce" shape="rect">Exelixis, Inc.</a> (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal trial, which showed that CABOMETYX® (cabozantinib) provided significant improvements in progression-free survival (PFS) versus placebo in patients with previously treated advanced neuroendocrine tumors (NET) regardless of functional status. These data will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting to be http://www.streetinsider.com/Press+Releases/Exelixis+Announces+Results+from+Subgroup+Analysis+of+Phase+3+CABINET+Pivotal+Trial+Evaluating+CABOMETYX%C2%AE+%28cabozantinib%29+in+Non-Functional+and+Functional+Neuroendocrine+Tumors+at+ASCO+2026/26577214.html Sat, 30 May 2026 10:00:00 -0400 A.19655944 A.50216726 A.60001765 EXEL O.00180634 O.03307993 O.20738543 O.21612337 http://www.streetinsider.com/Press+Releases/Exelixis+Announces+Results+from+Subgroup+Analysis+of+Phase+3+CABINET+Pivotal+Trial+Evaluating+CABOMETYX%C2%AE+%28cabozantinib%29+in+Non-Functional+and+Functional+Neuroendocrine+Tumors+at+ASCO+2026/26577214.html <p class="bwalignc"> <i>– CABOMETYX significantly reduced the risk of disease progression or death by 74% and 60% in patients with non-functional and functional advanced NET, respectively, versus placebo –</i> </p> <p> ALAMEDA, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.exelixis.com%2F&amp;esheet=54544202&amp;newsitemid=20260529816966&amp;lan=en-US&amp;anchor=Exelixis%2C+Inc.&amp;index=1&amp;md5=f477e6e10704015cd700297fbc4c73ce" shape="rect">Exelixis, Inc.</a> (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal trial, which showed that CABOMETYX® (cabozantinib) provided significant improvements in progression-free survival (PFS) versus placebo in patients with previously treated advanced neuroendocrine tumors (NET) regardless of functional status. These data will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting to be http://www.streetinsider.com/Press+Releases/Exelixis+Announces+Results+from+Subgroup+Analysis+of+Phase+3+CABINET+Pivotal+Trial+Evaluating+CABOMETYX%C2%AE+%28cabozantinib%29+in+Non-Functional+and+Functional+Neuroendocrine+Tumors+at+ASCO+2026/26577214.html Sat, 30 May 2026 10:00:00 -0400 A.19655944 A.50216726 A.60001765 EXEL O.00180634 O.03307993 O.20738543 O.21612337 http://www.streetinsider.com/Business+Wire/Exelixis+Announces+Results+from+Subgroup+Analysis+of+Phase+3+CABINET+Pivotal+Trial+Evaluating+CABOMETYX%C2%AE+%28cabozantinib%29+in+Non-Functional+and+Functional+Neuroendocrine+Tumors+at+ASCO+2026/26577214.html <p class="bwalignc"> <i>– CABOMETYX significantly reduced the risk of disease progression or death by 74% and 60% in patients with non-functional and functional advanced NET, respectively, versus placebo –</i> </p> <p> ALAMEDA, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.exelixis.com%2F&amp;esheet=54544202&amp;newsitemid=20260529816966&amp;lan=en-US&amp;anchor=Exelixis%2C+Inc.&amp;index=1&amp;md5=f477e6e10704015cd700297fbc4c73ce" shape="rect">Exelixis, Inc.</a> (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal trial, which showed that CABOMETYX® (cabozantinib) provided significant improvements in progression-free survival (PFS) versus placebo in patients with previously treated advanced neuroendocrine tumors (NET) regardless of functional status. These data will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting to be http://www.streetinsider.com/Business+Wire/Exelixis+Announces+Results+from+Subgroup+Analysis+of+Phase+3+CABINET+Pivotal+Trial+Evaluating+CABOMETYX%C2%AE+%28cabozantinib%29+in+Non-Functional+and+Functional+Neuroendocrine+Tumors+at+ASCO+2026/26577214.html Sat, 30 May 2026 10:00:00 -0400 A.19655944 A.50216726 A.60001765 EXEL O.00180634 O.03307993 O.20738543 O.21612337 http://www.streetinsider.com/Business+Wire/Exelixis+Announces+Results+from+Subgroup+Analysis+of+Phase+3+CABINET+Pivotal+Trial+Evaluating+CABOMETYX%C2%AE+%28cabozantinib%29+in+Non-Functional+and+Functional+Neuroendocrine+Tumors+at+ASCO+2026/26577214.html <p class="bwalignc"> <i>– CABOMETYX significantly reduced the risk of disease progression or death by 74% and 60% in patients with non-functional and functional advanced NET, respectively, versus placebo –</i> </p> <p> ALAMEDA, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.exelixis.com%2F&amp;esheet=54544202&amp;newsitemid=20260529816966&amp;lan=en-US&amp;anchor=Exelixis%2C+Inc.&amp;index=1&amp;md5=f477e6e10704015cd700297fbc4c73ce" shape="rect">Exelixis, Inc.</a> (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal trial, which showed that CABOMETYX® (cabozantinib) provided significant improvements in progression-free survival (PFS) versus placebo in patients with previously treated advanced neuroendocrine tumors (NET) regardless of functional status. These data will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting to be http://www.streetinsider.com/Business+Wire/Exelixis+Announces+Results+from+Subgroup+Analysis+of+Phase+3+CABINET+Pivotal+Trial+Evaluating+CABOMETYX%C2%AE+%28cabozantinib%29+in+Non-Functional+and+Functional+Neuroendocrine+Tumors+at+ASCO+2026/26577214.html Sat, 30 May 2026 10:00:00 -0400 A.19655944 A.50216726 A.60001765 EXEL O.00180634 O.03307993 O.20738543 O.21612337 http://www.streetinsider.com/Business+Wire/Exelixis+Announces+Results+from+Subgroup+Analysis+of+Phase+3+CABINET+Pivotal+Trial+Evaluating+CABOMETYX%C2%AE+%28cabozantinib%29+in+Non-Functional+and+Functional+Neuroendocrine+Tumors+at+ASCO+2026/26577214.html <p class="bwalignc"> <i>– CABOMETYX significantly reduced the risk of disease progression or death by 74% and 60% in patients with non-functional and functional advanced NET, respectively, versus placebo –</i> </p> <p> ALAMEDA, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.exelixis.com%2F&amp;esheet=54544202&amp;newsitemid=20260529816966&amp;lan=en-US&amp;anchor=Exelixis%2C+Inc.&amp;index=1&amp;md5=f477e6e10704015cd700297fbc4c73ce" shape="rect">Exelixis, Inc.</a> (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal trial, which showed that CABOMETYX® (cabozantinib) provided significant improvements in progression-free survival (PFS) versus placebo in patients with previously treated advanced neuroendocrine tumors (NET) regardless of functional status. These data will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting to be http://www.streetinsider.com/Business+Wire/Exelixis+Announces+Results+from+Subgroup+Analysis+of+Phase+3+CABINET+Pivotal+Trial+Evaluating+CABOMETYX%C2%AE+%28cabozantinib%29+in+Non-Functional+and+Functional+Neuroendocrine+Tumors+at+ASCO+2026/26577214.html Sat, 30 May 2026 10:00:00 -0400 A.19655944 A.50216726 A.60001765 EXEL O.00180634 O.03307993 O.20738543 O.21612337 http://www.streetinsider.com/Business+Wire/Exelixis+Announces+Results+from+Subgroup+Analysis+of+Phase+3+CABINET+Pivotal+Trial+Evaluating+CABOMETYX%C2%AE+%28cabozantinib%29+in+Non-Functional+and+Functional+Neuroendocrine+Tumors+at+ASCO+2026/26577214.html <p class="bwalignc"> <i>– CABOMETYX significantly reduced the risk of disease progression or death by 74% and 60% in patients with non-functional and functional advanced NET, respectively, versus placebo –</i> </p> <p> ALAMEDA, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.exelixis.com%2F&amp;esheet=54544202&amp;newsitemid=20260529816966&amp;lan=en-US&amp;anchor=Exelixis%2C+Inc.&amp;index=1&amp;md5=f477e6e10704015cd700297fbc4c73ce" shape="rect">Exelixis, Inc.</a> (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal trial, which showed that CABOMETYX® (cabozantinib) provided significant improvements in progression-free survival (PFS) versus placebo in patients with previously treated advanced neuroendocrine tumors (NET) regardless of functional status. These data will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting to be http://www.streetinsider.com/Business+Wire/Exelixis+Announces+Results+from+Subgroup+Analysis+of+Phase+3+CABINET+Pivotal+Trial+Evaluating+CABOMETYX%C2%AE+%28cabozantinib%29+in+Non-Functional+and+Functional+Neuroendocrine+Tumors+at+ASCO+2026/26577214.html Sat, 30 May 2026 10:00:00 -0400 A.19655944 A.50216726 A.60001765 EXEL O.00180634 O.03307993 O.20738543 O.21612337 http://www.streetinsider.com/Business+Wire/Exelixis+Announces+Results+from+Subgroup+Analysis+of+Phase+3+CABINET+Pivotal+Trial+Evaluating+CABOMETYX%C2%AE+%28cabozantinib%29+in+Non-Functional+and+Functional+Neuroendocrine+Tumors+at+ASCO+2026/26577214.html <p class="bwalignc"> <i>– CABOMETYX significantly reduced the risk of disease progression or death by 74% and 60% in patients with non-functional and functional advanced NET, respectively, versus placebo –</i> </p> <p> ALAMEDA, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.exelixis.com%2F&amp;esheet=54544202&amp;newsitemid=20260529816966&amp;lan=en-US&amp;anchor=Exelixis%2C+Inc.&amp;index=1&amp;md5=f477e6e10704015cd700297fbc4c73ce" shape="rect">Exelixis, Inc.</a> (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal trial, which showed that CABOMETYX® (cabozantinib) provided significant improvements in progression-free survival (PFS) versus placebo in patients with previously treated advanced neuroendocrine tumors (NET) regardless of functional status. These data will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting to be http://www.streetinsider.com/Business+Wire/Exelixis+Announces+Results+from+Subgroup+Analysis+of+Phase+3+CABINET+Pivotal+Trial+Evaluating+CABOMETYX%C2%AE+%28cabozantinib%29+in+Non-Functional+and+Functional+Neuroendocrine+Tumors+at+ASCO+2026/26577214.html Sat, 30 May 2026 10:00:00 -0400 A.19655944 A.50216726 A.60001765 EXEL O.00180634 O.03307993 O.20738543 O.21612337